Intensive multimodal ketogenic metabolic therapy in glioblastoma: A clinical trial
{{output}}
Background: Glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype, has a median overall survival of 11-14 months despite standard treatment. Ketogenic metabolic interventions that lower the glucose ketone index (GKI) may im... ...
